ARTICLE | Company News
Zynaxis, ALK A/S deal
October 30, 1995 8:00 AM UTC
ALK (Horsholm, Denmark) received exclusive rights to evaluate and develop ZNXS's oral vaccine technologies to deliver bioactive substances to treat allergies. ZNXS will receive $1 million in upfront fees plus research support, milestones, and royalties. ...